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Abstract
Purpose of Review Randomized controlled trials (RCTs) in
heart failure (HF) are becoming increasingly complex and
expensive to conduct and if positive deliver expensive therapy
tested only in selected populations.
Recent Findings Electronic health records and clinical cardio-
vascular quality registries are providing opportunities for
pragmatic and registry-based prospective randomized clinical
trials (RRCTs). Simplified regulatory, ethics, and consent pro-
cedures; recruitment integrated into real-world care; and sim-
plified or automated baseline and outcome collection allow
assessment of study power and feasibility, fast and efficient
recruitment, delivery of generalizable findings at low cost, and
potentially evidence-based and novel use of generic drugs
with low costs to society.
Summary There have been no RRCTs in HF to date. Major
challenges include generating funding, international collabo-
ration, and the monitoring of safety and adherence for chronic
HF treatments. Here, we use the Spironolactone Initiation
Registry Randomized Interventional Trial in Heart Failure
with Preserved Ejection Fraction (SPIRRIT-HFpEF), to be
conducted in the Swedish Heart Failure Registry, to exemplify
the advantages and challenges of HF RRCTs.
Keywords Heart failure . Registry . Prospective randomized
clinical trial . Pragmatic clinical trial . Registry-based
pragmatic trial . Registry-based prospective randomized
clinical trial . Cost
Introduction
Challenges in Heart Failure
Heart failure (HF) affects 2% of the population and up to 20%
of the elderly [1], is the most common cause of hospitalization
[2•], and is associated with mortality of approximately 20% at
1 year [3]. The prevalence will increase with an aging popu-
lation, and direct costs for HF are expected to increase three-
fold between 2010 and 2030 [4].
In HF with reduced ejection fraction (HFrEF), a generation
of trials of drug and device therapy has substantially improved
prognosis [5, 6]. A major challenge in this phenotype has
become proper utilization of existing interventions and im-
proved implementation in under-served patient groups
[7–11] as well as testing efficacy in previously excluded pop-
ulations such as those with chronic kidney disease or
hyperkalemia [12].
In contrast, HF with preserved EF (HFpEF) affects about
half of the HF population [5, 13, 14•, 15], is increasing in
prevalence, and will be the dominant form in the future [16].
Neurohormonal antagonist drugs that are now generic and
inexpensive appear promising [3, 17–19], but have not con-
vincingly been demonstrated to be beneficial in trials [20–23],
and evidence-based therapy for HFpEF has been identified as
“the greatest unmet need in cardiovascular medicine” [24••].
Furthermore, positive outcome trials have generally included
patients with EF ≤40%, whereas EF would be considered
preserved or normal only if ≥50% [25], leaving a mid-range
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category recently recognized as in particular need of further
study [5, 14•] and where neurohormonal antagonist drugs may
be reasonably expected to have potential benefit [26, 27].
Acute HF (AHF) is considered a distinct phenotype
[28–30]. Like in chronic HFpEF, prognosis has not improved
over time. Over 50% of patients are dischargedwith unresolved
symptoms, and within 60 days, 50% have again worsening
symptoms, 25% are re-hospitalized, and over 10% have died
[1, 31]. As in HFpEF, trials of novel interventions have been
largely unsuccessful. There are multiple supportive generic and
inexpensive treatments with class IIa–IIb recommendations in
guidelines but no underlying evidence [5, 6, 30].
The Complexity of the Randomized Controlled Trial
A foundation for contemporary clinical decision-making is the
evidence from prospective randomized clinical trials (RCTs),
which have transformedmedical practice over the last 70 years
[32•]. When patients are randomized to intervention and con-
trol groups, bias and confounding are eliminated, and causal-
ity between the intervention and the outcome is established.
Indeed, the establishment of RCTs and evidence-based medi-
cine has been ranked among the most important medical dis-
coveries of any kind, together with, e.g., vaccines, antibiotics,
and the discovery of DNA [33].
However, while the concept of randomization is simple,
RCTs have become increasingly large, complex, and expen-
sive, whichmay threaten their very existence [34]. Design and
reporting of RCTs is sub-optimal. Of 96,346 studies registered
in ClinicalTrials.gov between 2007 and 2010, a majority were
small and with heterogeneous reporting of methodology [35].
Among 13,327 trials between 2008 and 2013, only 13% re-
ported results within 12 months of completion [36]. Among
244 extramural trials funded by the National Heart, Lung, and
Blood Institute (NHLBI) and completed between 2000 and
2011, only 64% had been published by 2012 and median time
to publication was 25 months [37]. Although RCTs in cardio-
vascular (CV) medicine have transformed CV care, in a re-
view of 16 disease-specific, diagnostic, and interventional CV
guidelines, only 12% of recommendations were level A (with
HF the highest at 26% and valvular disease the lowest at
0.3%), and 48% of recommendations were level C [38].
Registry Studies Serve Many Functions but Are
Observational
CV disease is common and associated with significant event
rates, and there is a plethora of available interventions. This
lends itself to and indeed demands systematic quality
reporting, and registries in cardiovascular medicine have
evolved over the last 20–30 years [39–41, 42•]. Registries
serve many functions including quality reporting and im-
provement; benchmarking and performance measures; assess-
ment of practice patterns and trends, outliers, and safety sig-
nals; and patient empowerment and standardization and pro-
motion of equality of and access to care. They provide exten-
sive generalizable (externally valid) data at low cost and high
efficiency [39–41, 42•, 43•, 44] (Fig. 1) and are suitable for
studying clinical associations, risk markers, potential risk fac-
tors, and risk scores [44–46]. HF registries including the
SwedishHeart Failure Registry (SwedeHF) [7–9, 47–62] have
characterized use of evidence-based interventions in different
regions and contributed to improved utilization, and recently,
we showed that enrolment in a HF quality registry, SwedeHF,
was associated with lower mortality specifically explained by
improved use of evidence-based CV and HF interventions
[43•].
Clinical registries are part of real-world routine care
and may therefore in comparison to clinical trial databases
be limited by missing data, lower data quality, and lack of
adjudication. Data not missing at random (NMAR) intro-
duce bias and confounding but can be addressed by mul-
tiple imputation. Due to the complexity of the data, sta-
tistical methods are often more complex and may produce
a “black box” impression and be intimidating for the clin-
ical reader. However, in contrast to trial databases, regis-
tries are representative of most patients, which increases
generalizability and external validity.
However, the most important limitation of observational
studies is the lack of randomization of interventions, and thus
the inability to determine treatment efficacy [40, 63]. It has
been argued that the magnitude of associations in observation-
al studies generally are similar to the magnitude of efficacy in
RCTs [64, 65], but the lack of randomization inevitably pro-
duces bias and confounding [40, 63]. In a study of the associ-
ations between renin-angiotensin-system antagonist use and
mortality in SwedeHF, the hazard ratio for death in HFrEF
was 0.80 (95% CI 0.74–0.86; p<0.001) [18], which precisely
matches that in a large meta-analysis of RCTs in HFrEF [66].
The propensity score-matched hazard ratio in HFpEF was
0.91 (0.85–0.98; p=0.008). However, although this closely
matches the nominal hazard ratios for the primary outcomes
in CHARM-Preserved (0.89; 0.77–1.03; p= 0.118) [20],
PEP-CHF (0.92; 0.70–1.21; p=0.545) [21], and TOPCAT
(0.89; 0.77–1.04; p=0.14) [23], these trials did not reach sta-
tistical significance, and renin-angiotensin-aldosterone system
inhibition is not recommended specifically for HFpEF [5, 6].
Pragmatic Clinical Trials
The evaluative or pragmatic clinical trial (PCT) was originally
conceived to answer questions faced by decision makers and
was distinguished from mechanistic or explanatory trials [67].
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However, even conventional phase 3 RCTs are primarily eval-
uative. There are mechanistically sound phase 2 HF trials with
positive surrogate endpoints that have failed in phase 3.
Conversely, interventions such as sacubitril/valsartan [68]
were effective in phase 3 in the absence of preceding phase
2 trials and with little understanding of mechanisms responsi-
ble for the clinical benefit.
PCTs are now more broadly considered those with large
sample sizes; representative populations and generalizable
and relevant outcomes; efficient use of existing resources;
simplified operations (limited monitoring, safety reporting,
trial-specific assessments, and regulatory and compliance doc-
umentation); baseline and if possible outcome data collection
embedded in routine care setting or using telephone or auto-
mated follow-up; leveraging of electronic health records
(EHRs) and registries; and simplified case report and in-
formed consent forms [39–41, 69•, 70, 71]. The pragmatic
features in trials exist inevitably on a spectrum, and many
trials may be considered hybrid. The Pragmatic–Explanatory
Continuum Indicator Summary (PRECIS) tools has been de-
veloped for characterization of pragmatic trials along this
spectrum [72].
The literature describes numerous PCTs for diverse
conditions and interventions [73•, 74]. In the CV field,
the GISSI investigators’ trial of thrombolytics in myocar-
dial infarction [75] and the International Studies of Infarct
Survival (ISIS) [76] were early pragmatic trials, as were
ALLHAT [77] and SAFE-PCI [78]. The ongoing
ADAPTABLE (Aspirin Dosing: A Patient-centric Trial
Assessing the Benefits and Long-term Effectiveness) trial
from the Patient-Centered Outcomes Research Institute’s
(PCORI) National Patient-Centered Clinical Research
Network [79•] is a chronic intervention PCT enrolling
20,000 patients and is notable for efficient leveraging of
electronic health records data.
However, with the exception of SAFE-PCI, these PCTs
have not utilized registries, which have the added benefit of
baseline and in some case outcome data being embedded in
routine clinical care or accessible by automatic linking of data
sources. Existing registries in heterogeneous health systems
collect baseline data but often do not have access to outcomes.
In HF, the US Get With The Guidelines (GWTG)-HF registry
has been associated with improved utilization of HF interven-
tions [54], but we are not aware of efficient and reliable ways of
linking outcomes to this registry. There have been some smaller
pragmatic HF trials in disease management and self-care
[80–82] but none with drug or device interventions. The
NHLBI-sponsored Heart Failure Network has conducted sev-
eral trials at comparatively low cost but has to our knowledge
not incorporated specific pragmatic features. ASCEND-HF
was managed by a consortium of academic research organiza-
tions (AROs) rather than contract research organizations
(CROs), but most other aspects of the trial were conventional,
and the intervention, nesiritide, was not chronic [83].
Fig. 1 Characteristics or RCTs and registries, and advantages of RRCTs.
Each item is discussed in text. RCT prospective randomized controlled
trial, RRCT registry-based prospective randomized controlled trial, CRO
contract research organization, HF heart failure, M million, ARO
academic research organization
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Limitations of RCTS and How They Can
Be Mitigated in RRCTS: Future Directions
Swedish Registries
The Swedish universal standardized publicly funded health
care system [84] together with unique personal identification
numbers [85] is uniquely suited for an extensive registry in-
frastructure. Sweden has currently 96 quality registries funded
by the federal and regional governments, coordinated by the
Swedish Association of Local Authorities and Regions (www.
skl.se) and described at www.kvalitetsregister.se. Among
cardiovascular registries are the Swedish Web-system for
Enhancement and Development of Evidence-based care in
Heart disease Evaluated According to Recommended
Therapies (SWEDEHEART, www.ucr.uu.se/swedeheart)
which includes myocardial infarction, percutaneous coronary
and valve interventions, cardiac surgery, secondary
prevention, and cardiogenetic disorders, and the Swedish
Heart Failure Registry (SwedeHF, www.SwedeHF.se).
SwedeHF was founded in 2000 and is an ongoing
syndrome-specific nationwide voluntary quality reporting reg-
istry with close to 110,000 registrations in 70,000 unique pa-
tients since 2000. The inclusion criterion is physician-judged
HF. EF is recorded as <30, 30–39, 40–49, and ≥50%. Patients
are enrolled at discharge from hospital or at out-patient encoun-
ters. Patients are informed of registration and opt-out is possi-
ble, but there is no written informed consent. Approximately
100 baseline clinical and medication variables are recorded in
an online case report form (CRF) managed by Uppsala Clinical
Research Center (UCR, www.ucr.se).
Sweden also provides governmental registries on health,
medications, demographics, and national statistics. The
Swedish Board of Health and Welfare (www.socialstyrelsen.
se) maintains the mandatory National Patient Registry (NPR),
Cause of Death Registry, and Dispensed Drug Registry. NPR
collects International Classification of Diseases (ICD) diag-
nostic and procedure codes since 1987. The positive predic-
tive values for most diagnoses are 85–95% [85]; a heart failure
diagnosis was verified in 86–91% of cases [86]. NPR can be
linked to the quality registries to provide additional baseline
comorbidity data as well as cause-specific hospitalization and
morbidity outcomes. The cause of death registry is based on
death certificates and records both mode and underlying
causes of death. It is not validated against medical records
but each death certificate is manually reviewed and inconsis-
tencies corrected. The Dispensed Drug Registry is maintained
by the Swedish Board of Health and Welfare and contains
details on all prescriptions actually dispensed by a pharmacy
since 1 July 2005. All pharmacies are required to participate
by law and coverage is 100%.
Thus, both baseline and outcome data can be obtained by
linking quality registries to these administrative databases.
Using this infrastructure, Sweden with addition of Iceland
and one Danish site conducted the landmark RRCT
Thrombus Aspiration in ST-Elevation Myocardial Infarction
in Scandinavia (TASTE) trial, described in detail elsewhere
[40, 87, 88]. There are additional ongoing trials in acute cor-
onary syndromes, including DETOX-AMI (oxygen) and
VALIDATE (bivalirudin vs. heparin) [40]. However, these
are all testing acute interventions and do not require any
follow-up or monitoring of chronic care. There have been no
RRCTS to date in HF.
The Spironolactone Initiation Registry Randomized
Interventional Trial in Heart Failure with Preserved Ejection
Fraction (SPIRRIT-HFpEF) is an RRCT under development
in SwedeHF. It is prospective randomized, multicenter, safety/
efficacy, parallel assignment, intention-to-treat, open-label
treatment, phase 4, event-driven interventional trial in
HFpEF, testing spironolactone + usual care vs. usual care
alone in patients with HF and EF ≥40%. To our knowledge,
this is the first registry-based trial in heart failure. In the fol-
lowing, we present our view of the limitations of RCTs and the
potential of RRCTs, and SPIRRIT-HFpEF will be used as an
illustration and each section is summarized in Fig. 1. The
RRCT platform and data linking for RRCT in SwedeHF is
illustrated in Fig. 2.
Regulatory Requirements and Non-essential Data
While necessary and justified from a good clinical practice
(GCP) perspective, regulatory requirements are also becom-
ing increasingly complex and both hindering trials [89••, 90,
91••, 92•] and indeed stimulating the growth of an entire
for-profit contract research organization (CRO) industry.
Sponsors and investigators often include extensive
sub-studies and data collection, study visits, and question-
naires with little relevance to the main objectives but adding
to cost and complexity [93•]. In CV phase III trials, there was a
50% increase in procedures and 30% increase in work burden
between 2000–2003 and 2004–2007 [89••]. About 25% of
trial procedures support regulatory requirements and noncore
data [93•]. The typical trial in 2012 involved 13 endpoints,
169 case report form pages, and 175 days of on-site monitor-
ing [94••]. The IMPROVE-IT trial [95] enrolled 18,144 pa-
tients and entailed 300,000 patient visits, 2.7 million CRF
forms completed, over 15,000 SAEs processed, 14,709 events
sent for adjudication, over 30,000 monitoring visits, 33 inves-
tigator meetings, and 9 DMC reviews (Dr. Michael Blazing,
Duke University, personal communication).
Thus, a central feature of the RRCT is to reduce this com-
plexity. SPIRRIT-HFpEF is sponsored by and will be man-
aged by the non-profit academic research organization (ARO)
UCR. Spironolactone is an approved and familiar drug, and in
this phase 4 trial, there will be limited reporting of SAEs. Site
monitoring will be risk-based and focus on consent
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procedures and inclusion/exclusion criteria. Randomization
integrity is ensured by a central online randomization module,
safety is monitored as an outcome, and the primary and all
other endpoints are obtained automatically from national
registries.
Ethics and Informed Consent
The ethics and institutional review board review and approval
in conventional RCTs are generally site-specific, complex,
expensive, and time-consuming (Fig. 1). Single central ethics
approval is more efficient and not inconsistent with GCP [69•,
70, 71]. Sweden has a national centralized ethics committee
organization (www.epn.se) with local committees, each of
which can provide a single centralized approval for
multicenter studies (Fig. 1).
Written informed consent is a central tenet of GCP but also
by definition excludes a proportion of otherwise eligible pa-
tients, slows recruitment and introduces selection bias, and limits
generalizability [73•]. In large PCTs, it may be impractical with
conventional consent procedures, and careful risk determination
and the nature of the interventions may in some case allow
waived or modified informed consent [73•, 96•, 97]. Individual
consent may not be required for interventions that focus on
clinicians or health systems, such as cluster-randomized trials
[73•, 96•, 97], e.g., the Post-Myocardial Infarction Free Rx
Event and Economic Evaluation, MI FREEE [98], or for e.g.,
patients with impaired consciousness, e.g., the Corticosteroid
Randomization after Significant Head Injury trial, CRASH
[99]. An integrated consent procedure has been proposed where
consent is verbal and provided in the context of other patient
decisions in usual care [97]. In TASTE, oral consent was col-
lected prior to angiography, and written confirmation obtained
after the randomized procedure. SPIRRIT-HFpEF has a single
intervention, follow-up only by telephone (and automatically
from registries) and no sub-studies, and a short and simple writ-
ten consent form.
Study Population, Screening, and Enrolment
In conventional RCTs, pre-screening is manual and often op-
portunistic (i.e., occurs as potential patients are encountered)
and therefore inefficient and unpredictable (Fig. 1).
Participation in trials has fallen over time, and the patient
response rate to a screening invitation is generally less than
10% [73•] and likely lower in heart failure, where patients are
often older, comorbid, and frail. Large trials generally include
many hundred sites, but only 10% of clinicians participate in
trials [100] and recruitment in CV trials is generally consider-
ably less than 1 [101••] and in HF less than 0.4 patients per site
per month, yielding a total of less than 20 per site [100]. This
is a particular problem in the USA andWestern Europe, whose
share in multinational trial enrolment is declining [32•, 67,
73•, 102]. Embedding trial recruitment, randomization, and
outcomes ascertainment into routine clinical care would im-
prove enrolment and generalizability of trial findings [34, 71].
Fig. 2 The integrated platform for RRCTs in the Swedish Heart Failure
Registry. New patients are entered into the registry, and the platform
screens and determines eligibility for both [1] previously entered and
living patients, and [2•] online as new patients are entered. Eligibility is
fed back to the investigator in the registry, in the form of [1] lists of
existing eligible patients and [2•] online as entered patients are
determined to be eligible. The investigator collects informed consent,
the platform randomizes online and the investigator implements the
randomized assignment and follows the patient in routine clinical care
(with or without extra trial-specific follow-up). The baseline data entered
into the registry as part of routine care together with randomized
assignment are fed into a separate electronic data capture (EDC) system
in the RRCT platform. The unique personal ID number is fed to the
independent registries in the Swedish Board of Health and Welfare,
which feeds back outcomes (deaths and causes, hospitalization and
causes, new diagnoses, and medication use and randomized medication
assignment adherence) to the EDC in the platform. Baseline and outcome
data are then analyzed, provided to an independent data monitoring
committee (DMC), and published. SwedeHF The Swedish Heart
Failure Registry, RRCT registry-based randomized controlled trial
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The EHR and in particular registries enable automated, online,
and real-time screening (Fig. 1).
SwedeHF is widely accepted as an integral part of routine
care, and there is broad participation throughout Sweden. This
ensures both that the SPIRRIT-HFpEF trial will be supported
and that the findings will be generalizable to Northern
European patients with HFpEF. Patients will be automatically
screened and recruited at enrolment in the registry (discharge
from hospital or out-patient visit) and from a pool of living
eligible patients, provided to each center by UCR (Figs. 1 and
2). Thus, early enrolment can be rapid from these existing
patients. Known event rates in eligible patients in the registry
facilitate the power calculation; known existing eligible pa-
tients and historical enrolment rates facilitate assessment of
feasibility of recruitment. The only unknown is the proportion
consenting. In TASTE, 60% of all STEMI patients and 77% of
all eligible patients were included [88].
Many HFpEF and AHF trials may have failed in part because
of suboptimal eligibility criteria or outcomes. The RRCTconcept
will not solve this problem but the existing registry can perform
simulations that provide extensive data on the types of patients
and events to expect given different eligibility criteria (Fig. 1).
This use of registries is beginning to be recognized by and ap-
pealing to industry, whereas actual industry-sponsored trial con-
duct has not yet occurred in the registries.
Intervention: Novel Treatment vs. Novel Use of Existing
Treatment
Conventional RCTs are complex in part because they test
novel interventions, proprietary unapproved drugs, or devices.
Outcome adjudication and safety reporting become para-
mount. However, for HFpEF, there are numerous existing,
approved, and generic interventions that may be tested in a
novel use concept (Fig. 1). Spironolactone is approved for
heart failure (without specifying EF). TOPCATwas promising
but does not convincingly support its use, and there is consen-
sus that a new trial such as SPIRRIT-HFpEF is needed [103].
Spironolactone will be prescribed by investigators and filled
by patients at conventional pharmacies. Drug costs in Sweden
are paid by the patient out of pocket up to an annual maximum
of 2200 SEK (∼$240). Most patients will be at the max at all
times of filling and re-filling study drug prescriptions. In rare
occasions when study drug will incur personal costs, the local
sites and in turn the sponsor will reimburse.
There are other interventions such as renin-angiotensin sys-
tem (RAS) antagonists and diuretic regimens that are suitable
for testing in HFpEF RRCTs. Many empiric interventions in
AHF such as oxygen, diuretic regimens, and vasodilators are
also inexpensive, familiar, and suitable for AHF RRCTs.
Similarly, SwedeHF is suitable for prospective randomized
or cluster-randomized trials of structured care, such as disease
management, biomarker-driven, or self-care.
Intervention: Acute vs. Chronic
TASTE and other PCTs tested acute intervention, with poten-
tial effects in the short or long term. No trial-specific follow-up
may be needed if outcomes can be reliably obtained from reg-
istries. For chronic drug treatments, such as spironolactone in
HFpEF, follow-up is needed both for adherence and safety.
Adherence to spironolactone (and control) assignment will be
monitored and enforced at four trial-specific follow-up tele-
phone calls, at all usual care encounters, and in the Dispensed
Drug Registry. Crossover will be defined for the control group
as de novo spironolactone or eplerenone use. Prescriptions in
Sweden are for 3-month durations but patients may have been
intermittently adherent or taken reduced doses. Therefore, be-
yond information from direct patient contact, crossover will be
defined in a treated patient as failure to refill within 6 months
from baseline or from last dispensation, where crossover will be
set to 3 months from randomization or last refill.
Control, Placebo, and Blinding
In a double-blind RCT, randomization eliminates selection
bias, and confounding and blinding eliminates treatment
(placebo) and diagnostic bias. However, placebo entails con-
siderable cost for procurement, packaging, labeling, transport,
and storage, and accountability, and more importantly, in-
creases the work-load on investigators and impairs recruit-
ment. There are numerous examples of randomized but
non-blinded trials that have met regulatory requirements and
changed guidelines and standard of care, such as the RE-LY
trial of dabigatran for atrial fibrillation [104], and trials of left
ventricular assist devices in advanced HF [105, 106].
Pragmatic trials often do not include blinding and in order to
minimize bias, focus on objective outcomes such as all-cause
or CV mortality [73•] and/or use blinded endpoints in the
prospective randomized open-label blinded endpoint
(PROBE) design.
Outcomes
Conventional RCTs often entail multiple endpoints, depen-
dent on extensive event adjudication. Because interventions
and drugs are novel, safety and SAE and AE reporting are
extensive, and even trial endpoints are often concurrently re-
ported as SAEs [94••]. While an independent clinical end-
points committee adjudicating non-fatal events is essential,
the inclusion of numerous non-primary and complex end-
points often add unduly to the data collection and reporting
requirements and burden to investigators.
Although many EHRs and registries may be suitable for
patient identification, recruitment, and automated collection of
baseline variables, a major limitation is the lack of efficient,
reliable, and complete collection of outcomes. In addition to
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the large network of clinical quality registries in Sweden, the
mandatory and complete coverage government health and sta-
tistical registries enable collection of outcomes (Fig. 1). In
SPIRRIT, CV, HF, and all-cause hospitalization will be auto-
matically collected from NPR, and CV and all-cause death
from the cause of death registry (Fig. 2). Safety outcomes in
aggregate wil l be reported from NPR. However,
SPIRRIT-HFpEF will have some components of a conven-
tional trial, specifically the monitoring of safety by measuring
creatinine and potassium and the adjudication of CV death.
Efficacy vs. Effectiveness
Conventional clinical trials are generally mechanistic and ex-
planatory and optimized to determine efficacy [73•]. Already
in 1967, concerns were raised that this design did not ade-
quately inform clinical practice, with calls for pragmatic and
evaluative trials [107]. Conventional RCTs systematically and
non-randomly exclude certain patient groups such as the el-
derly and women [108, 109]. Indeed, the median age in many
HF trials has been less than 70 years, as compared to 77 in
HFpEF, 74 in HFmrEF, and 72 in HFrEF in SwedeHF. In
PEP-CHF [21] and I-PRESERVE [22], the median
NT-proBNP ranged 320–453 ng/L, whereas in observational
studies of RAS-antagonists and beta blockers in SwedeHF, it
was over 2000 ng/L [3, 18]. A conventional trial with exten-
sive follow-up and time commitment on part of the patient
will entail a healthy volunteer effect [73•]. The slow enrol-
ment in conventional trials limits generalizability and validity
of results [110] (Fig. 1). Conventional trials are further biased
by experienced investigators and follow-up care that is more
rigorous than routine care, leading to overestimation of benefit
and underestimation of harm. From a patient and societal per-
spective, a broad view of any intervention, including magni-
tude of effect, real-world effectiveness, and cost-effectiveness,
is important [73•].
A pragmatic or registry-based trial is embedded in rou-
tine clinical care. Although registry coverage is not com-
plete and trial participation within a registry is selective,
the population included in an RRCT will be more repre-
sentative of the general HF population and findings more
generalizable (Fig. 1). Mineralocorticoid receptor antago-
nists (MRAs) are highly effective in HFrEF trials, but
there has been concern that in the real world, monitoring
of renal function and electrolytes is not in adherence to
guidelines [111], and observational studies suggest that
MRAs may not be associated with benefit in the real
world [112, 113]. MRAs remain class IA recommendation
in HFrEF [5, 6] but these observations highlight the po-
tential for differences in efficacy and effectiveness and
indeed present the question of whether trials should adapt
to real-world circumstances, or real-world care should
adapt to trials.
Costs of Developing and Testing a Novel Intervention
vs. Testing a New Use Intervention
The cost of trials are added to the cost of drug development.
Taking a single drug to market may cost $350million, and given
that 95% of drugs studied in humans fail to ultimately demon-
strate safety and efficacy, the average cost may be higher than $5
billion [114]. The cost of inventing and developing a novel drug
has been estimated to over $1 billion, and for 100 pharmaceutical
companies reviewed by Forbes in 2013, the R&D costs per drug
ranged from $15 million to $13 billion [114]. Industry R&D
development is declining, and average peak-year sales of inno-
vative products were forecasted to decline from $900 million in
2012 to $600 million in 2015 [115].
Much of this cost is related to the trial conduct itself. An
estimated 18% of trial budgets are spent on supplementary or
exploratory endpoints, and extraneous data collected in clini-
cal trials cost drug developers $4 billion to $6 billion annually
[116]. CV trials generally cost over $50 million [100] and
mega trials in coronary disease, HF, and diabetes much more.
A recent conventional trial of >14,000 diabetic patients en-
rolled at 660 sites cost nearly $250 million with monitoring
constituting >$56 million (23%) [89••].
PCTs have been less expensive. The 7-year 42,000-patient
ALLHAT cost $120 million to complete [67]. The
ADAPTABLE trial that leverages EHR data to target enroll-
ment of 20,000 patients over a shorter enrollment period is
estimated to cost ≈$14 to 18 million with reduced costs for
trial management and monitoring and increased costs for in-
formatics [79•, 89••]. With access to both baseline and out-
come data, RRCTs have unique possibilities to reduce cost
further (Figs. 1 and 2). The incremental cost (beyond regular
operations of the registry) in TASTE was $300,000, corre-
sponding to about $50 per patient [41, 100].
Costs of Using Novel vs. New Use Treatments
Given the need to recoup investment, the cost to patients and
society of novel patented drugs brought to market are also
high (Fig. 1). In HFrEF, the novel sacubitril/valsartan
(Entresto®) costs $5 to >$10 per day in different Western
countries. Despite convincing evidence from PARADIGM-HF,
clear guidelines [5, 117], and emerging favorable
cost-effectiveness data [118], reimbursement for sacubitril/
valsartan remains variable. The high or low uptake of novel
drugs such as sacubitril/valsartan over the next few years may
serve as encouragement or deterrence, respectively, for industry
to engage in new drug development for HF.
In contrast, HFpEF is uniquely positioned for testing of
novel use of existing generic neurohormonal antagonist drugs.
The cost of spironolactone in Sweden is less than 10 US cents
per day and if proven effective in HFpEF, can have a tremen-
dous impact for the many patients with HFpEF at low costs to
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society (Fig. 1). Similarly in AHF, trial-proven optimized use
of the many generic and inexpensive drugs that are currently
used empirically may deliver substantial benefit at low cost.
Limitations of the RRCTand Future Challenges
As PCTs and RRCTs are encouraged by multiple stakeholders
and becoming more familiar, it is important to recognize and
address limitations, the importance of which are still difficult
to assess. Will these trials be of high enough quality? How do
we balance efficacy vs. effectiveness? As follow-up and mon-
itoring is minimized for chronic interventions, how do we
ensure the primary concern: safety to trial participants? How
do we address privacy in these large patient databases, and
will it be possible to reduce the need for informed consent?
How important is, and what are additional costs of, blinding?
Will pragmatic trials be able to assess effects on composite
and patient-reported outcome measures (PROM), which are
gaining in acceptance and importance, especially in chronic
conditions associated with poor quality of life such as
HFpEF? How can adjudication of these events be facilitated?
Although a unique strength of PCTs and RRCTs is unselective
inclusion and generalizable, relevant real-world findings,
these trials have not yet been conducted in multinational or
worldwide settings, limiting geographic generalizability. As
we have developed the RRCT concept in Sweden, we also
recognize that our population of 10 million is small, and it is
in our interest to expand our RRCT methodology and RRCT
platforms to other regions of the world.
The Major Future Challenge: Funding
Although RRCTS are inexpensive, there remain fundamental
components of GCP and trial infrastructure that entail consid-
erable expense, generally beyond that possible from individual
institutional or investigator grants. The medical products indus-
try and public funders have previously not focused on pragmat-
ic trials [67]. Industry has little incentive to fund RRCTs of
generic drugs. However, it seems it would be attractive to col-
laborate with academia and registries in different forms of hy-
brid PCTor RRCT settings. Stakeholders including public reg-
ulatory, and funding agencies appear to recognize the need for
trial reform [34, 37, 41, 67, 69•, 70, 71, 90, 92•, 94••, 96•,
101••] and should be willing to fund pragmatic trials.
However, NIH extramural funding was an estimated 70% to
basic and only 30% to clinical research of all types [119]. Now
is the time for both industry and public funders to leverage the
emerging PCT and RRCT infrastructure for efficiency and in-
expensiveness, leading to new treatments for patients combined
with savings for shareholders and the public.
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